Successful therapeutic plasma exchange in a 3.2-kg body weight neonate with atypical hemolytic uremic syndrome

J Clin Apher. 2011;26(3):162-5. doi: 10.1002/jca.20283. Epub 2011 Feb 14.

Abstract

Atypical hemolytic uremic syndrome (aHUS) is a rare form of complement dysregulation disease, and recently various reports have shown that it is associated with one or more mutations in the complement regulatory genes including complement factor H (CFH). Plasma exchange is a therapeutic option for adult patients, but not for a very young infant because of a potential side effect of therapeutic plasma exchange (TPE) itself. Herein, we describe a case of successful treatment of early onset aHUS associated with a novel CFH mutation with total 21 sessions of TPE over a period of 46 days in 3.2 kg 23-day-old neonate.

Publication types

  • Case Reports

MeSH terms

  • Atypical Hemolytic Uremic Syndrome
  • Body Weight
  • Complement Factor H / genetics
  • Female
  • Hemolytic-Uremic Syndrome / therapy*
  • Humans
  • Infant, Newborn
  • Mutation
  • Plasma Exchange*
  • Treatment Outcome

Substances

  • Complement Factor H